Thank you. I only have five minutes, so I'll have to hurry.
Dr. Attaran, you started out by mentioning that one of the main obstacles here is pricing, the fact that it is not financially viable for Canadian generic companies to provide generic drugs. Yet we're hearing a slightly different point of view. Could you expand a little on that argument, please?